@article{6d1fdf6597dd489ca58fddbb1eaecf01,
title = "Transcutaneous yellow fever vaccination of subjects with or without atopic dermatitis",
abstract = "Background Atopic dermatitis (AD) is a common inflammatory skin disease with a global prevalence ranging from 3% to 20%. Patients with AD have an increased risk for complications after viral infection (eg, herpes simplex virus), and vaccination of patients with AD with live vaccinia virus is contraindicated because of a heightened risk of eczema vaccinatum, a rare but potentially lethal complication associated with smallpox vaccination. Objective We sought to develop a better understanding of immunity to cutaneous viral infection in patients with AD. Methods In a double-blind randomized study we investigated the safety and immunogenicity of live attenuated yellow fever virus (YFV) vaccination of nonatopic subjects and patients with AD after standard subcutaneous inoculation or transcutaneous vaccination administered with a bifurcated needle. Viremia, neutralizing antibody, and antiviral T-cell responses were analyzed for up to 30 days after vaccination. Results YFV vaccination administered through either route was well tolerated. Subcutaneous vaccination resulted in higher seroconversion rates than transcutaneous vaccination but elicited similar antiviral antibody levels and T-cell responses in both the nonatopic and AD groups. After transcutaneous vaccination, both groups mounted similar neutralizing antibody responses, but patients with AD demonstrated lower antiviral T-cell responses by 30 days after vaccination. Among transcutaneously vaccinated subjects, a significant inverse correlation between baseline IgE levels and the magnitude of antiviral antibody and CD4 + T-cell responses was observed. Conclusions YFV vaccination of patients with AD through the transcutaneous route revealed that high baseline IgE levels provide a potential biomarker for predicting reduced virus-specific immune memory after transcutaneous infection with a live virus.",
keywords = "IgE, T-cell memory, Yellow fever virus, antibody, atopic dermatitis",
author = "Slifka, {Mark K.} and Leung, {Donald Y.M.} and Erika Hammarlund and Rau{\'e}, {Hans Peter} and Simpson, {Eric L.} and Susan Tofte and Shahana Baig-Lewis and Gloria David and Henry Lynn and Rob Woolson and Tissa Hata and Henry Milgrom and Jon Hanifin",
note = "Funding Information: Supported by federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services contract no. HHSN266200400029C (to D.Y.M.L., T.H., J.H., and M.K.S.) and HHSN26620400033C and Oregon National Primate Research Center grant 8P51 OD011092-53 (to M.K.S.). Funding Information: Disclosure of potential conflict of interest: M. K. Slifka has been supported by one or more grants from the National Institutes of Health (NIH; HHSN266200400029C ); is a Board member for, is employed by, and owns stock/stock options in Najit Technologies; and has received one or more grants from or has one or more grants pending with and has one or more patents (planned, pending, or issued) with OHSU/Najit Technologies . D. Y. M. Leung is employed by National Jewish Health and has received research grants from the NIH . E. Hammarlund has been supported by the NIH ( HHSN266200400029C ) and owns shares in Najit Technologies. H.-P. Rau{\'e} has been supported by one or more grants from the NIH ( HHSN266200400029C ). E. L. Simpson has consultancy arrangements with Anacor, Asubio, Brickell Biotech, Galderma, Medicis, and Regeneron; is employed by Oregon Health & Science University; and has received one or more grants from or has one or more grants pending with Amgen, Celgene, Galderma, and Regeneron . S. Tofte is employed by Oregon Health & Science University. G. David and R. Woolson have received one or more payments for writing or reviewing the manuscript from the National Institute of Allergy and Infectious Diseases ( HHSN272201000017C ). H. Lynn has received one or more fees for participation from and has received one or more payments for writing or reviewing from the NIH ( HHSN272201000017C ). T. Hata has been supported by one or more grants from and has received support for travel from the NIH . J. Hanifin is a member of the Merck Valeant Elocon Advisory Board Expert Panel; has consultancy arrangements with GlaxoSmithKline, Pfizer, and Chugai Pharma USA; is employed by Oregon Health & Science University; and has received one or more grants from or has one or more grants pending with Merck Sharp & Dohme Corp and Asubio . The rest of the authors declare that they have no relevant conflicts of interest. ",
year = "2014",
month = feb,
doi = "10.1016/j.jaci.2013.10.037",
language = "English (US)",
volume = "133",
pages = "439--447",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "2",
}